<DOC>
	<DOCNO>NCT01620502</DOCNO>
	<brief_summary>The first part double-blind placebo-controlled trial identify effect omega-3 polyunsaturated fatty acid ( PUFAs ) prevention IFN-induced depression . The second part double-blind trial identify antidepressant effect omega-3 PUFAs patient IFN-induced depression .</brief_summary>
	<brief_title>N-3 Polyunsaturated Fatty Acids Prevention Treatment IFN-induced Depression</brief_title>
	<detailed_description>We do preliminary analysis 63 HCV patient receive IFN-α therapy enrol current NSC project ( NSC95-2320-B-039-037-MY3 ) find patient later develop IFN-α-induced depression ( case group , 21/63 ) low PUFA level start IFN-α therapy control group ( p=0.024 ) . In addition , trend negative correlation ( r=-0.224 ; p=0.078 ) baseline DHA level high score BDI IFN therapy whole group . These finding indicate n-3 PUFAs might play protective factor . This 3-year proposal divide 2 clinical study . In study 1 , aim test prophylactic effect n-3 PUFAs ( EPA : 3.5 g/d DHA : 1.75 g/d versus placebo : high oleic oil ) IFN-α-induced sickness behaviour depressive symptom , two-week , double-blind , placebo-controlled trial 152 patient HCV start IFN-α therapy . In study 2 , test antidepressant effect n-3 PUFAs ( EPA : 3.5 g/d DHA : 1.75 g/d versus placebo : high oleic oil ) IFN-α-induced depression IFN-α therapy , eight-week , double-blind , placebo-controlled trial 80 HCV patient already develop depression .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Eligible participant adult patient chronic HCV , assess hepatologists refer IFNα therapy capacity willingness give write informed consent Patients exclude major depressive episode assessment Any history preexist psychotic disorder ( e.g . schizophrenia bipolar disorder ) Alcohol drug dependence within one year entry study Seizure disorder evidence unstable substantial coexist medical condition ( e.g . cardiovascular , endocrine , haematological , renal , neurological disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>